Sylvester Comprehensive Cancer Center

Validation of the International Working Group 2023 response criteria for higher risk myelodysplastic syndromes/neoplasms using the International Consortium for Myelodysplastic Syndromes VALIDATE database and a randomized phase III trial

Response assessment criteria in patients with higher-risk myelodysplastic syndromes/neoplasms (HR-MDS) have been updated in the 2023 International Working Group (IWG) criteria. However, validation of these criteria has been limited to date. We analyzed overall survival (OS) by be...

Positive selection screen identifies natural product β-catenin inactivators

Many genetically validated targets in cancer, including the transcription factor β-catenin (β-cat), have historically been viewed as undruggable. Cell-based phenotypic screening of chemical compounds can reveal unanticipated biological and pharmacological principles. Natural prod...

Influence of Variant of Uncertain Significance (VUS) Genetic Testing Results on Mastectomy Choice in Lumpectomy-Eligible Patients

Abstract Purpose Our objective was to evaluate whether having a germline variant of uncertain significance (VUS) influenced the decision to undergo bilateral mastectomy (BLMast) among lumpectomy-eligible patients with unilateral breast cancer. Methods This retrospective cohort st...

TM184C is a GPCR-like regulator of intercellular exchange and autophagy

Sequence similarity underlies most protein annotation, yet many functions remain hidden beyond detectable homology1–3. By mining millions of AlphaFold2 models4,5, we identify two human families of ‘superdark’ seven-transmembrane proteins—TM184 and PRRT—with structural homology to...

3D-Printed Poly(Lactic-co-Glycolic Acid) Binder-Based Self-Hardening Calcium Phosphate Bone Scaffolds

Three-dimensionally (3D)-printed alpha-tricalcium phosphate (α-TCP) scaffolds, fabricated through a low-temperature hydrothermal dissolution-precipitation process, replicate the structural and compositional features of native bone. Reinforcing hydrothermally processed α-TCP with...

Variation in meningioma recurrence risk estimates across observational cohorts: the influence of calendar time, WHO classifications, geographical settings, and healthcare systems

Abstract Purpose Recurrence risk estimates underpin meningioma research, including molecular classification and clinical trial benchmarking, yet are often based on retrospective or historical data. The aim of this study was to assess the variation of recurrence risk estimates acr...

Clinical Relevance of Calcifications in Osteosarcoma Lung Metastases: Correlations Among Radiological Patterns, Histological Subtypes, and Chemotherapy Responses

Background/Objectives: Osteosarcoma is a rare malignancy and the most common primary malignant bone tumor. Metastases commonly affect the lungs and are associated with reduced life expectancy. Calcifications can be present within a metastatic nodule at baseline or can appear duri...

Extended Follow-Up of Botensilimab Plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer Without Active Liver Metastases

PURPOSE: Microsatellite-stable metastatic colorectal cancer (MSS mCRC) has limited treatment options and responds poorly to conventional immunotherapy. We report extended follow-up results from a fully-enrolled, phase 1b cohort evaluating botensilimab (BOT; Fc-enhanced anti-CTLA-...

Impact of Response to Hypomethylating Agent‐Based Therapy on Survival Outcomes in the Context of Baseline Clinical‐Molecular Risk and Transplant Status in Patients With Higher‐Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Consortium for MDS (icMDS)

Baseline IPSS-M risk, response to hypomethylating agent (HMA) therapy, and receipt of allogeneic stem cell transplant (allo-HCT) have all been individually shown to impact overall survival (OS) in patients with myelodysplastic syndromes (MDS). However, the prognostic impact of re...

Paediatric therapeutic development workshop on osteosarcoma

The fourth Paediatric Therapeutic Development Workshop focused on osteosarcoma, the most common primary bone cancer in children and young adults. Current treatment of osteosarcoma comprises surgery and chemotherapy. Outcome has shown very little improvement over the last four dec...

Label-free optical biomarker for prostate cancer diagnosis

Reprogramming of cellular metabolism in cancer leads to changes in the activity of metabolic coenzymes NAD(P)H and FAD which can be used as markers of tumorigenesis and metastasis. NAD(P)H and FAD form coupled redox pair and regulator of mitochondrial energy metabolism. Since NAD...

Bone marrow failure syndromes across the age spectrum: diagnostic and therapeutic principles

Bone marrow failure syndromes (BMFS) are a diverse group of disorders that commonly present with pancytopenia and require a structured approach to evaluation. Initial assessment focuses on excluding reversible causes, followed by consideration of inherited and acquired conditions...

Racial and Ethnic Differences in Classic and 11-Oxygenated Androgens in Men

BACKGROUND: Androgen-dependent prostate pathology, including prostate cancer and benign prostatic hyperplasia, differs in prevalence and phenotype across races/ethnicities. Adrenal-derived 11-oxygenated C19 steroids (11-oxyandrogens) are relevant to several androgen-dependent pat...

Emerging Treatments in Bone Tumors: Lessons Learned from the ESMO Annual Meeting

Primary bone sarcomas are rare, heterogeneous malignancies with limited therapeutic options, particularly in metastatic disease where outcomes remain poor. This study synthesizes current literature to evaluate emerging therapeutic strategies and biological determinants of respons...

Bio‐Inspired Biopolymeric Implantable Platform for Localized and Sustained Drug Delivery in Solid Tumor Treatment

ABSTRACT The development of biocompatible and biodegradable drug delivery systems remains a major challenge in cancer therapy, particularly for the localized and sustained release of poorly soluble, unstable, and highly toxic compounds. 7‐Ethyl‐10‐hydroxycamptothecin (SN‐38), the...